Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and is on track for a New Drug Application (NDA) filing in the third quarter of 2026. The company has secured funding through 2029 to support ongoing Phase 3 trials for major depressive disorder, bipolar depression, and pain, while also building its commercial capabilities. Despite trading at a premium reflecting its de-risked assets and platform potential, Xenon faces regulatory, commercial, and psychiatric indication risks going forward.
Shopify reported strong Q2 2026 earnings, surpassing analyst expectations thanks to significant growth in AI-driven commerce. AI-driven traffic and orders to Shopify stores tripled year-over-year, boosting confidence in the company's AI innovation. S...
Freightos Limited reported Q2 results surpassing expectations with an EPS of -$0.03 versus -$0.05 expected and record revenue of $7.7 million, driven by a 19% increase in core platform revenue. The company narrowed its adjusted EBITDA loss to $2 mill...
Evercore ISI raised Ross Stores' price target to $276, suggesting a 12.5% upside from its current $245.36 price. The boost reflects strong expectations for Q2, with projected revenues of $6.10 billion (up 10.7%) and earnings per share of $1.92 (up 23...
Rosen Law Firm is investigating a class action lawsuit against Elauwit Connection, Inc. after the company disclosed errors in its 2025 financial statements related to network construction revenue. This disclosure caused Elauwit's stock to drop by 6.8...
Shares of memory and storage chipmakers rose sharply after reports that the US government is urging domestic tech firms to avoid purchasing conventional memory chips from Chinese suppliers. Micron Technology, Sandisk, Western Digital, and Seagate all...
